CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: INITIAL RESULTS OF A MULTICENTER, OPEN LABEL PHASE II STUDY

被引：0
|
作者：
Bringhen, S. [1 ]
Federica, C. [1 ]
Petrucci, M. [2 ]
Gay, F. [1 ]
Federico, V. [2 ]
Conticello, C. [2 ]
Pantani, L. [2 ]
Montefusco, V. [2 ]
Benevolo, G. [2 ]
Aschero, S. [1 ]
Offidani, M. [2 ]
Villani, O. [2 ]
Siniscalchi, A. [2 ]
Rossi, D. [2 ]
Magarotto, V. [1 ]
Sonneveld, P. [3 ]
Boccadoro, M. [1 ]
Palumbo, A. [1 ]
机构：
[1] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[2] GIMEMA, Italian Multiple Myeloma Network, Rome, Italy
[3] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S578
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [31] Cyclophosphamide/dexamethasone as initial treatment in newly diagnosed symptomatic multiple myeloma - A pilot study
    Romeril, K.
    Carter, J.
    Wood, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 174 - 174
  • [32] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
    Gay, Francesca
    Musto, Pellegrino
    Rota-Scalabrini, Delia
    Bertamini, Luca
    Belotti, Angelo
    Galli, Monica
    Offidani, Massimo
    Zamagni, Elena
    Ledda, Antonio
    Grasso, Mariella
    Ballanti, Stelvio
    Spadano, Antonio
    Cea, Michele
    Patriarca, Francesca
    D'Agostino, Mattia
    Capra, Andrea
    Giuliani, Nicola
    de Fabritiis, Paolo
    Aquino, Sara
    Palmas, Angelo
    Gamberi, Barbara
    Zambello, Renato
    Petrucci, Maria Teresa
    Corradini, Paolo
    Cavo, Michele
    Boccadoro, Mario
    LANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720
  • [33] Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients
    Pawlyn, Charlotte
    Davies, Faith
    Cairns, David
    Striha, Alina
    Hockaday, Anna
    Kishore, Bhuvan
    Garg, Mamta
    Williams, Cathy
    Karunanithi, Kamaraj
    Lindsay, Jindriska
    Jones, John
    Jenner, Matthew
    Russell, Nigel
    Cook, Gordon
    Kaiser, Martin
    Drayson, Mark
    Owen, Roger
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E2
  • [34] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    BLOOD, 2021, 138
  • [35] A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.
    Leng, Siyang
    Wei, Alexander
    Assal, Amer
    Bhutani, Divaya
    Baliko, Gregory
    Gould, Julia
    Shelton, Ryan J.
    Kelly, Shannon
    Otap, Daniel
    Mapara, Markus Y.
    Lentzsch, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
    Chavez, Jule Franve Vasquez
    Mendoza, Rossana Esther Ruiz
    Llerena, Karina Mayra Aliaga
    Valencia, Fernando
    Enriquez, Daniel
    Palacios, Victor
    Casanova, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [38] Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Bhutani, Manisha
    House, Monika
    He, Jiaxian
    Atrash, Shebli
    Foureau, David M.
    Paul, Barry
    Friend, Reed
    Symanowski, James T.
    Norek, Sarah
    Begic, Xhevahire
    Acampora, Donna
    Farmer, Katherine K.
    Syfert, Carrie Ann
    Pineda-Roman, Mauricio
    Voorhees, Peter
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [39] PHASE II CLINICAL AND CORRELATIVE STUDY OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE EXTENDED DOSING (CRD-R) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
    Korde, N.
    Zingone, A.
    Kwok, M.
    Manasanch, E.
    Wu, P.
    Tageja, N.
    Bhutani, M.
    Flanders, A.
    Costello, R.
    Mulquin, M.
    Zuchlinski, D.
    Roschewski, M.
    Maric, I.
    Calvo, K.
    Braylan, R.
    Yuan, C.
    Stetler-Stevenson, M.
    Arthur, D.
    Xi, L.
    Raffeld, M.
    Lindenberg, M.
    Choyke, P.
    Kurdziel, K.
    Steinberg, S.
    Lee, M.
    Trepei, J.
    Landgren, O.
    HAEMATOLOGICA, 2013, 98 : 98 - 99
  • [40] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    Bringhen, S.
    D'Agostino, M.
    De Paoli, L.
    Montefusco, V.
    Liberati, A. M.
    Galieni, P.
    Grammatico, S.
    Muccio, V. E.
    Esma, F.
    De Angelis, C.
    Musto, P.
    Ballanti, S.
    Offidani, M.
    Petrucci, M. T.
    Gaidano, G.
    Corradini, P.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    LEUKEMIA, 2018, 32 (04) : 979 - 985
12345